InflaRx N-V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy InflaRx N-V stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IFRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
M1 Finance
- Commission-free stock and ETF trades
- No management fees
- Customizable portfolios with automatic rebalancing
InflaRx N-V stock price (NASDAQ: IFRX)
Use our graph to track the performance of IFRX stocks over time.InflaRx N-V shares at a glance
Latest market close | $4.21 |
---|---|
52-week range | $0.78 - $7.25 |
50-day moving average | $4.14 |
200-day moving average | $2.83 |
Wall St. target price | $9.63 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.65 |
Buy InflaRx N-V stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy InflaRx N-V stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
InflaRx N-V price performance over time
Historical closes compared with the close of $4.21 from 2023-06-02
1 week (2023-05-26) | 1.20% |
---|---|
1 month (2023-05-05) | -3.88% |
3 months (2023-03-03) | 131.32% |
6 months (2022-12-05) | 68.40% |
1 year (2022-06-03) | 186.39% |
---|---|
2 years (2021-06-04) | 34.50% |
3 years (2020-06-05) | 7.49 |
5 years (2018-06-05) | 37.33 |
InflaRx N-V financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -28.75% |
Return on equity TTM | -30.45% |
Profit margin | 0% |
Book value | $1.98 |
Market capitalisation | $247.9 million |
TTM: trailing 12 months
InflaRx N-V share dividends
We're not expecting InflaRx N-V to pay a dividend over the next 12 months.
InflaRx N-V share price volatility
Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $0.776 up to $7.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.9697. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).
InflaRx N-V overview
InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co.
InflaRx N-V in the news
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Frequently asked questions
What percentage of InflaRx N-V is owned by insiders or institutions?Currently 13.099% of InflaRx N-V shares are held by insiders and 19.324% by institutions. How many people work for InflaRx N-V?
Latest data suggests 44 work at InflaRx N-V. When does the fiscal year end for InflaRx N-V?
InflaRx N-V's fiscal year ends in December. Where is InflaRx N-V based?
InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745 What is InflaRx N-V's ISIN number?
InflaRx N-V's international securities identification number is: NL0012661870 What is InflaRx N-V's CUSIP number?
InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101
More guides on Finder
-
JP Morgan Personal Advisors review 2023
Access remote advice, planning and portfolio management from this established financial services company.
-
How to buy Energy Transfer Equity stock
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
-
How to buy Uranium Energy stock
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
-
How to buy Gold Royalty stock
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
Best online brokers & platforms to buy gold stocks in June 2023
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Ask an Expert